Publication: Allogeneic Stem Cell Transplantation For Children With Acquired Severe Aplastic Anaemia: A Retrospective Study By The Viva-Asia Blood And Marrow Transplantation Group
Issued Date
2013-08-01
Resource Type
ISSN
13652141
00071048
00071048
Other identifier(s)
2-s2.0-84880316491
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
British Journal of Haematology. Vol.162, No.3 (2013), 383-391
Suggested Citation
Jing Chen, Vincent Lee, Cheng Juan Luo, Alan Kwok Shing Chiang, Suradej Hongeng, Poh Lin Tan, Ah Moy Tan, Kleebsabai Sanpakit, Chun Fu Li, Anselm Chi wai Lee, Hsin Chieh Chua, Yasuhiro Okamoto Allogeneic Stem Cell Transplantation For Children With Acquired Severe Aplastic Anaemia: A Retrospective Study By The Viva-Asia Blood And Marrow Transplantation Group. British Journal of Haematology. Vol.162, No.3 (2013), 383-391. doi:10.1111/bjh.12405 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32245
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Allogeneic Stem Cell Transplantation For Children With Acquired Severe Aplastic Anaemia: A Retrospective Study By The Viva-Asia Blood And Marrow Transplantation Group
Other Contributor(s)
Shanghai Jiao Tong University School of Medicine
Prince of Wales Hospital Hong Kong
The University of Hong Kong Li Ka Shing Faculty of Medicine
Mahidol University
National University Health System
KK Women's And Children's Hospital
Southern Medical University
Mount Elizabeth Medical Centre
Kagoshima University Medical And Dental Hospital
Prince of Wales Hospital Hong Kong
The University of Hong Kong Li Ka Shing Faculty of Medicine
Mahidol University
National University Health System
KK Women's And Children's Hospital
Southern Medical University
Mount Elizabeth Medical Centre
Kagoshima University Medical And Dental Hospital
Abstract
We retrospectively analysed the outcomes of 127 children with acquired severe aplastic anaemia (SAA) who had received haematopoietic stem cell transplantation (HSCT) between 2000 and 2011 in one of the 10 Asia Pacific institutions. Fifty-three were matched sibling donor (MSD) and 74 were alternative donor (AD), including 22 matched unrelated donor, 32 mismatched unrelated donor and 20 mismatched related donor. With a median follow up 45·5 months (13-139) and when compared to the MSD group, AD recipients had more grade II-IV acute graft-versus-host disease (aGVHD; 14·3% vs. 32·8%, P = 0·029), but similar grade III-IV aGVHD (10·2% vs. 12·5%, P = 0·774), graft failure (GF) (15·1% vs. 15·5%, P = 0·658) and 5-year overall survival (90·6% vs. 83·7%, P = 0·251). As a source of stem cell, peripheral blood stem cells (PBSC) resulted in less GF (18% vs. 9·1% P = 0·013), similar grade II-IV aGVHD (28·1% vs. 17·4%, P = 0·258), chronic GVHD (25·8% vs. 29·3%, P = 0·822) and similar outcomes (89·7% vs. 82·4%, P =0 ·665) when compared to bone marrow (BM). In univariate analysis, GF (P < 0·001) and grade II-IV aGVHD (P = 0·009) were predictors of poor survival. In multivariate analysis, only GF was associated with poor survival (P = 0·012). The outcome of AD and PBSC HSCT were comparable to that of MSD and BM HSCT in the Asia Pacific region. © 2013 John Wiley & Sons Ltd.